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Background: Adult hematopoietic stem cells (HSCs) are maintained in a microenvironment, known as niche in the
endosteal regions of the bone marrow. This stem cell niche with low oxygen tension requires HSCs to adopt a
unique metabolic profile. We have recently demonstrated that mouse long-term hematopoietic stem cells (LT-HSCs)
utilize glycolysis instead of mitochondrial oxidative phosphorylation as their main energy source. However, the
metabolic phenotype of human hematopoietic progenitor and stem cells (HPSCs) remains unknown.
Results: We show that HPSCs have a similar metabolic phenotype, as shown by high rates of glycolysis, and low
rates of oxygen consumption. Fractionation of human mobilized peripheral blood cells based on their metabolic
footprint shows that cells with a low mitochondrial potential are highly enriched for HPSCs. Remarkably, low MP
cells had much better repopulation ability as compared to high MP cells. Moreover, similar to their murine
counterparts, we show that Hif-1α is upregulated in human HPSCs, where it is transcriptionally regulated by Meis1.
Finally, we show that Meis1 and its cofactors Pbx1 and HoxA9 play an important role in transcriptional activation of
Hif-1α in a cooperative manner.
Conclusions: These findings highlight the unique metabolic properties of human HPSCs and the transcriptional
network that regulates their metabolic phenotype.
Keywords: Stem cells, Metabolism, Hypoxia, Hypoxic regulation of metabolism, Human hematopoietic progenitor
and stem cells, HPSCsBackground
HSCs are defined by their inherent capacity for self-
renewal and differentiation into all blood cell types.
Adult HSCs reside in regions of the bone marrow chal-
lenged by low oxygen tension (hypoxia), which is termed
“hypoxic niche” [1, 2]. We recently demonstrated that
mouse HSCs in this hypoxic niche adopt a glycolytic
metabolic profile, in which HSCs manifest lower rates of
oxygen consumption, lower ATP content, and increased
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levels [3–5].
HIF-1 regulates various aspects of metabolism from
the oxidant stress response to regulation of glycolysis
and mitochondrial respiration [6–12]. HIF-1, a major
mediator of transcriptional response to hypoxia, is
composed of O2 sensitive HIF-1α and constitutively ac-
tive HIF-1β subunits [13–15]. Conditional deletion of
HIF-1α in HSCs results in various defects such as loss
of quiescence and progressive decline in HSC number
following bone marrow transplantations and aging [4].
In addition hypoxic cultures promote the production of
hematopoietic progenitors and enhance HSC expansion
[1, 16, 17]. HIF-1α protein is mainly stabilized during
hypoxia but normoxic upregulation of HIF-1α has also
been reported [14, 18–25]. We recently demonstrated that
Meis1 transactivates HIF-1α expression via a conservedarticle distributed under the terms of the Creative Commons Attribution License
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[3], and regulates mouse HSC metabolism [26].
Several reports suggest that homeobox protein Meis1
plays important roles in HPSC biology [27–32]. Homozy-
gous mutant mice for Meis1 die during gestation with de-
fects in hematopoiesis which results in decline in myeloid,
lymphoid, and multipotent progenitors [33–35]. Meis1 is
also associated with leukemogenesis in humans with a fre-
quent up-regulation in primary acute myeloid leukemia
(AML) [29, 30] and acute lymphoblastic leukemia (ALL)
samples [36]. We recently showed that mouse LT-HSCs
express Meis1 where a great majority of Meis1+ HSCs
coexpress Hif-1α [3]. Previous reports indicate that
Meis1 interacts with the cofactors Pbx1 and HoxA9 in
HSCs, which are known regulators of hematopoiesis
[27, 28, 37–48]. However, the cooperative role of Meis1
and its cofactors in regulation of HIF-1 is unknown.
In the current report, we demonstrate that human
HPSCs have a metabolic profile characterized by low mito-
chondrial oxidative phosphorylation, dependence on glyco-
lytic metabolism, and upregulation of hypoxia-responsive
pathways. We show that the metabolic phenotype of hu-
man HPSCs is mediated in part via transcriptional activa-
tion of Hif-1α by Meis1 and its cofactors Pbx1 and HoxA9.
Results
Metabolic profile of human HPSCs
HSCs have been reported to reside in hypoxic niches
and this suggested that HSCs require adopting unique
metabolic properties. Here, we demonstrate that human
HPSCs (Lin−CD34+CD38−CD90+ cells) from G-CSF
mobilized peripheral blood (MPB) have lower rates of
mitochondrial respiration. The overall oxygen consump-
tion by HPSCs is significantly lower compared to MPB
mononuclear cells (Fig. 1a). Consistently, human HPSCs
have lower ATP content (Fig. 1b). In addition, Fig. 1c
shows that the rate of glycolysis is significantly higher
in HPSCs compared to the MPB mononuclear cells,
suggesting that human HPSCs rely primarily on glyco-
lytic metabolism instead of mitochondrial oxidative
phosphorylation.
Next we sought to profile human MPB HPSCs based
on their mitochondrial proton gradient as an index of
overall mitochondrial respiration. Similar to mouse HSCs,
the majority of the human Lin−CD34+CD38−CD90+ cells
(74 %) fell within a defined flow-cytometry gate which cor-
responds to 7–9 % of total G-CSF mobilized human per-
ipheral blood cells (Fig. 1d and Additional file 1: Fig. S1a
and b). Cells in this gate were characterized by low mito-
chondrial potential (low MP) while the majority of the
remaining MPB populations fell within a high mito-
chondrial potential (high MP) (Fig. 1e-f ). Furthermore,
we determined percentages of different lineages within low
and high MP cells of MPB (Fig. 1g and Additional file 1:Fig. S1c and d). The results showed the low MP cells only
contained a few B cells (CD19, 7.9 %) and myeloid cells
(Mac-1, 17.05 %). The high MP cells had lower percentage
of B cells (CD19, 2.4 %), but much higher percentage of
myeloid cells (Mac-1, 81.65 %). This result indicated that
there were less differentiated cells in low MP cells com-
pared to high MP cells, which was consistent with enrich-
ment of HPSCs in low MP cells.
Low MP cells are primed for hypoxic niche
To characterize the metabolic properties of cells in the
low and high MP gates, we performed a PCR array for
hypoxia related gene expression in freshly isolated low
and high MP cells. Under normoxic conditions, the low
MP cells were characterized by significant upregulation
of numerous hypoxia-inducible genes and regulatory gly-
colysis genes including Hif-1α (Fig. 2a). These results are
not only supportive of the metabolic phenotype of low
MP cells, but also suggest that the low MP cells are
primed to handle hypoxic stresses. In addition, expres-
sion profile of the Hif-1α regulatory genes is in favor of
stabilization of Hif-1α protein in low MP cells (Fig. 2b).
PHD2, which is responsible for hydroxylation of Hif-1α
resulting in its ubiquitination and degradation, was sig-
nificantly (p < 0.05) downregulated in the low MP cells.
Conversely, SIAH2 and VDU2, two stabilizers of Hif-1α
were significantly (p < 0.05) upregulated in low MP cells
compared to high MP cells. These results support the
higher levels of Hif-1α and the higher expression of
Hif-1α target genes in low MP cells.
Increased Hif-1α expression in low MP cells suggests
that low MP cells could confer survival advantage at
hypoxia. Thus, we measured the viability of low MP and
high MP cells at normoxia and hypoxia (Fig. 2c). Sur-
vival of low MP cells at hypoxic condition, but not at
normoxic condition, was much higher than that of high
MP cells. The increased survival under hypoxic condi-
tions by low MP cells in vitro suggested that low MP
cells in physiological hypoxia could have higher survival
ability. To further confirm this, we examined the apoptotic
status of low and high MP cells at different conditions by
staining with anti-Annexin V antibodies. Consistently, we
demonstrated that there was a dramatic increase of apop-
tosis in high MP cells at hypoxic condition, but not at nor-
moxic condition (Additional file 2: Fig. S2a). In addition,
low MP cells consumed less oxygen compared to high MP
cells at normoxia while there is no significant difference
at hypoxia (Fig. 2d). Moreover, measurement of glycoly-
sis rate of low MP and high MP cells showed that the
glycolytic rate is significantly increased under hypoxia,
which indicated the low MP cells preferred to glycolysis
as the energy source in the physiologic niche (Fig. 2e).
Moreover, we used the Seahorse XF96 extracellular flux
analyzer to measure the oxygen consumption rate (OCR)
Fig. 1 (See legend on next page.)
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Fig. 1 Metabolic profile of human HPSCs. a) Oxygen consumption of Lin−CD34+CD38−CD90+ HPSCs and human mobilized peripheral blood cells
(MPB Cells) demonstrating lower rates of oxygen consumption by HPSCs (n = 3). b) ATP level of HPSCs and MPB Cells demonstrating lower ATP
levels in HPSCs (n = 3). c) Glycolytic flux of HPSCs and MPB Cells demonstrating higher rates of glycolysis in HPSCs (n = 3). d) Flow cytometry
profile of MPB mononuclear cells stained with mitotracker. Note populations with different mitotracker fluorescence. e) Mitotracker profile of
human HPSCs. The majority of human HPSCs (73–75 %) are localized to a unique population (7–9 %) of total human MPB mononuclear cells with
low mitochondrial potential (low MP). f) Quantification of the percent of human HPSCs residing in low MP cells and high MP cells demonstrates
significant enrichment of human HPSCs in low MP gate. g) Characterization of different lineages within low and high MP cells of MPB. The
low MP cells only contained a few B cells (CD19, 7.9 %) and myeloid cells (Mac-1, 17.05 %). The high MP cells had lower percentage of B cells
(CD19, 2.4 %), but much higher percentage of myeloid cells (Mac-1, 81.65 %) (n =3).*p < 0.05, **p < 0.01
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production indicative of glycolysis (extracellular acidifica-
tion rate, ECAR). As shown in Fig. 2f and g, low MP cells
showed a significantly lower OCR rate as compared to
high MP cells. In contrast, low MP cells showed a signifi-
cantly higher ECAR rate, indicative of higher glycolytic
metabolism. This data further revealed low MP cells using
glycolysis as primary energy source.
Together, these results indicate that low MP cells are
characterized by baseline upregulation of glycolytic and
hypoxia inducible genes, which suggests adaptation of
human HPSCs to glycolysis as the major source of en-
ergy production.Characterization of stem cell profile of metabolically
sorted cells
Given HSCs demonstrating distinct metabolic proper-
ties, we tested whether this metabolic footprint could
enrich for HPSCs. Following flow cytometric separation
of low and high MP cells, we utilized colony formation
assay to test stem cell properties of low MP cells. Equal
numbers of low and high MP cells were plated in meth-
ocult media for 12 days. Then, number and type of col-
onies were evaluated. Low MP cells had significantly
(p < 0.001) higher colony formation compared to high
MP cells (Fig. 3a). Additional classification of colony
types showed that the low MP cells produced a higher
percentage of CFU-GEMM type (mixed colonies) (Fig. 3b)
with lower percentages of BFU-E (Fig. 3c) and CFU-GM
(Fig. 3d) colonies than high MP cells. In addition to the
in vitro assays, we also performed repopulation assays
in vivo and demonstrated that low MP cells had much
higher engraftment as compared to high MP cells. This
provides the strong evidence that low MP cells are indeed
enriched for HSPCs (Fig. 3e and Additional file 2: Fig.
S2b). Furthermore, we evaluated the gene expression pro-
file of low and high MP cells by PCR array. Similar to their
mouse counterparts, low MP cells were characterized by
enrichment of HPSC associated stem cell markers and di-
minished lineage differentiation markers when compared
to high MP cells (Fig. 3f and g, respectively). These results
indicate that low MP cells are enriched for human HPSCs.Expression of Hif-1α and Meis1 in human HPSCs
In order to determine the molecular mechanism behind
glycolytic phenotype of human HPSCs and the expres-
sion of Hif-1α in low MP MPB cells, we evaluated the
expression pattern of Hif-1α and Meis1 in human MPB
mononuclear cells and HPSCs. Meis1 is a transcription
factor required for definitive hematopoiesis. We dem-
onstrated that Meis1 transcriptionally regulates Hif-1α
expression in mouse LT-HSCs [3]. However, whether
Meis1 plays any role in the regulation of Hif-1α in human
hematopoiesis was unknown. To address this question, we
first determined the expression of Meis1 in human MPB
mononuclear cells and HPSCs. Cells were fixed, perme-
abilized, and intracellularly stained by antibodies against
Hif-1α and Meis1 followed by flow cytometry analysis.
While about 5 % and 6 % of MPB mononuclear cells
express Hif-1α and Meis1, respectively (Fig. 4a, Fig. 4d
and Additional file 3: Fig. S3), a significantly higher
percent of HPSCs express Hif-1α (47 %) (Fig. 4b-c and
Additional file 4: Fig. S4) and Meis1 (48 %) (Fig. 4e-f
and Additional file 4: Fig. S4). In addition, approxi-
mately 80 % of Meis1+ MPB cells are Hif-1α positive
(Fig. 4g-h and Additional file 3: Fig. S3). This expres-
sion pattern was obtained after hours of MPB harvest,
which suggests that expression of Hif-1α in the MPB
cells is not secondary to the in vivo hypoxic niche in
the bone marrow.Regulation of Hif-1α by Meis1
Given the confirmed conserved Meis1 consensus binding
sequence in the Hif-1α intron [1] and the Meis1 expres-
sion in human hematopoietic cells, we sought to deter-
mine whether Meis1 is required for Hif-1α expression in
HPSCs. To this end, we used siRNA to knockdown Meis1
in Kasumi-1 cells (a human myeloid progenitor cell line
known to express Hif-1α at normoxic conditions [23]).
Upregulation of Meis1 or Hif-1α in low MP cells and in
Kasumi-1 cells was confirmed by real time PCR (Fig. 5a to
5c respectively) prior to siRNA experiments. Scrambled
Meis1 siRNA was used as control. 50 nM Meis1 siRNA
resulted in significant decrease of Meis1 mRNA levels
(5.2 +/− 1.0 fold reduction) (p < 0.05). Conistently, the
Fig. 2 (See legend on next page.)
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Fig. 2 Low MP Cells are primed for hypoxic niche. a) Real-time PCR array of low MP cells compared to high MP cells shows significant upregulation of
a number of hypoxia inducible genes in the low MP cells at normoxia. b) Expression of regulators of Hif-1α in low and high MP cells by RT-PCR. Note
the significant downregulation of the Hif-1α destabilizing enzyme PHD2 and the upregulation of two Hif-1α stabilizing enzymes SIAH2 and VDU2 in
the low MP cells. c) Survival of low MP cells under hypoxia: The viability of low MP cells under hypoxic condition, but not normoxic condition, was
much higher than that of high MP cells. d) Oxygen consumption by Low MP and High MP cells at normoxia and hypoxia. Low MP cells had lower
rates of oxygen consumption at normoxia compared to high MP cells, but no significant difference at hypoxia. e) Increased glycolysis rate of low MP
cells in vitro measured at hypoxia. Increased glycolytic rate under hypoxia by low MP cells suggest that low MP cells could respond to hypoxia via
increasing glycolysis, which indicated the low MP cells prefer glycolysis as the energy source in the physiologic hypoxic niche. f) Plots of oxygen
consumption rate (OCR) as a parameter of time in low MP cells and high MP cells. g) Extracellular acidification rate (ECAR) was plotted as a parameter
of time in low MP cells and high MP cells (n =3).*p < 0.05
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by western blotting (Additional file 5: Fig. S5). This was
associated with a significant downregulation of Hif-1α
mRNA (Fig. 5d), as well as reduced expression of glycolytic
genes downstream of Hif-1α including lactate dehydrogen-
ase (LDHA), Glut1 (SLC2A1), and phosphofructokinase
(PFKL) (Fig. 5e) (p < 0.05). Furthermore, knockdown of
Meis1 in Kasumi-1 cells demonstrated a relative meta-
bolic shift towards increased oxidative phosphorylation
in Kasumi-1 cells as shown by increased oxygen con-
sumption and ATP levels (Fig. 5f ) compared to nega-
tive control. These results demonstrate that Meis1 is
required for optimal expression of Hif-1α and its down-
stream target genes in human hematopoietic cells.Cooperation of Meis1 with Pbx1 and HoxA9 in the
regulation of Hif-1α expression
In addition to Meis1 binding motif in the Hif-1α intron,
we identified conserved putative Pbx1 (“TGAT”) and
HoxA9 (“ATAA”) binding motifs in close proximity to
consensus Meis1 binding site (Fig. 6a). Meis1, Pbx1
and HoxA9 pose interaction domains or motifs that
facilitate cooperation in gene activation. Given that
Meis1 is known to cooperate with Pbx1 and HoxA9
in gene activation, we tested the role of Pbx1 and
HoxA9 in the activation of Hif-1α. Using Hif-1α-
pGL2 luciferase reporter, which includes conserved
Meis1, Pbx1 and HoxA9 sites, we demonstrate a dose
dependent activation of Hif-1α by Pbx1 (Fig. 6b) and
HoxA9 (Fig. 6c) in addition to Meis1 as we showed
earlier [3]. This activation demonstrates dependence
on binding of Pbx1 or HoxA9 to its consensus binding se-
quences in the Hif-1α reporter as mutation of the seed se-
quences (PbxMut-Hif-1α-pGL2 or HoxMut-Hif-1α-pGL2
reporters, respectively) completely abolished the activation
of Hif-1α by Pbx1 or HoxA9 respectively. To test co-
operation of Meis1 with Pbx1 and HoxA9 in the Hif-1α
expression, we performed further luciferase assays using
different combinations of Meis1, Pbx1, and HoxA9
vectors. Here we demonstrate that Meis1, Pbx1 and
HoxA9 cooperate in the activation of Hif-1α (Hif-1α-pGL2
reporter) (Fig. 6d).To further characterize the interaction of Meis1 with
Pbx1 and HoxA9 proteins in the activation of Hif-1α, we
generated mutant Meis1 protein lacking Pbx1 inter-
action Motifs (PIM) and HoxA9 protein lacking Meis1
interaction domain (MID) (Fig. 6e). As shown Additional
file 6: Fig. S6, we could stably detect the expression of
Meis1, Meis1ΔPIM, HoxA9 and HoxaΔMID, which in-
dicated that deletion mutants of the proteins were stable in
our system. These mutant proteins allowed us to demon-
strate that protein-protein interaction between Meis1 and
Pbx1 as well as Meis1 and HoxA9 are required for tran-
scriptional activation of Hif-1α luciferase reporter by
Meis1, Pbx1 and HoxA9 (Fig. 6f). In summary, Hif-1α ex-
pression is regulated by cooperative activation of Meis1,
Pbx1 and HoxA9 (Fig. 6g). This activation is dependent on
consensus binding motifs located at Hif-1α intronic region.Discussion
Several studies indicated that human HPSCs reside in
hypoxic niches and are capable of surviving upon hyp-
oxic stress [1, 16, 17]. However, it is unclear if HPSCs
are endowed with distinct metabolic properties that con-
fer this hypoxic tolerance. In the current report, we
show that human HPSCs are localized to a flow cytome-
try gate characterized by low mitochondrial potential
(low MP). This population represents only 7–9 % of the
G-CSF mobilized human peripheral blood cells, but is
enriched for more than 70 % of human HPSCs as Lin
−CD34+CD38−CD90+ cells. Moreover, we confirm this
metabolic profile by demonstrating that human HPSCs
have lower ATP content, lower rates of oxygen con-
sumption, and use cytoplasmic glycolysis instead of
mitochondrial oxidative phosphorylation. Interestingly,
here we demonstrated that the glycolytic phenotype of
HPSCs persists in circulating cells, suggesting that the
metabolic phenotype of HSCs is a product of intrinsic
regulatory mechanisms and not just their environment.
Similar to their murine counterparts, this unique meta-
bolic profile is associated with upregulation of Hif-1α. It
is noteworthy that we found human HPSCs are localized
to the low MP gate even after G-CSF mobilization to the
peripheral blood, which indicates that HPSCs may have
Fig. 3 Low MP Cells are enriched for hematopoietic stem cells. In vitro colony forming assay using low and high MP human MPB cells. Panel a to
d shows the number of colonies derived from low and high MP cells after 12 days in methocult medium. Note the significantly higher number
of colonies derived from the low MP population. (n = 3, p < 0.001) Different types of colonies derived from low and high MP cells were analyzed.
b, c and d are the percentages of CFU-GEMM, BFU-E and CFU-GM respectively. e) FACS-sorted low MP cells and high MP cells were injected into
the tibia of sublethally irradiated NOD/SCID mice. The donor repopulation was shown after 2 months. f) Real Time PCR array of HPSC markers
comparing low MP cells to high MP cells. g) Real Time PCR array of differentiation markers comparing low MP to high MP cells. Note the enrichment
of a number of markers for HPSCs and the downregulation of differentiation markers. *p < 0.05, ***p < 0.001
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properties, other than their location in hypoxic niches.
Hif-1α as a master regulator of metabolism plays an
essential role in various aspects of adaptation to hypoxic
stress. Regulation of Hif-1α expression is well studied in
terms of its posttranslational stabilization during hypoxia,
however, little is known about its transcriptional regula-
tion. Previous reports by our group and others indicate
that Hif-1α is regulated at the transcription level not only
at hypoxia but also normoxia [3, 22, 49–51]. Here we
show that, the transcription factor Meis1 plays an import-
ant role in HPSC metabolism through transcriptional
regulation of Hif-1α in cooperation with its cofactors
Pbx1 and HoxA9. Meanwhile, we also noticed that anyone
of Meis1, Pbx1 or HoxA9 was able to upregulate Hif-1α at
transcription level (Fig. 6d). However, when one or more
mutated factor(s) plus another WT factor did not tran-
scriptionally upregulate Hif-1α (Fig. 6f). We speculated
that the expression of mutant forms of the any protein
might interrupt the action of any WT protein in transcrip-
tional regulation of Hif-1α. This might indicate that nor-
mal expression levels of these factors play an important
role in the synergistic effect in the expression of Hif-1α.Recently, our group recently demonstrated that Meis1 is
an important regulator of postnatal cardiomyocyte cell
cycle [52]. Intriguingly, we found that Pbx1 and HoxA9
were not expressed in postnatal cardiomyocytes, while
other AbdB-like paralogue of Hox genes seem to have an
expression pattern similar to Meis1. Therefore, it may be
that the transcriptional activity of Meis1 in various com-
partments is regulated through differential expression pat-
tern of its cofactors.Conclusions
In summary, our findings demonstrate the unique meta-
bolic properties of human HPSCs as compared to human
MPB mononuclear cells, as well as the transcriptional
network that regulates their metabolic phenotype. The
transcriptional regulation of Hif-1α by Meis1 and its
cofactors, and the metabolic shift that follows loss of
Meis1 suggest that the metabolic profile of human
HPSCs is an intrinsic characteristic of these cells and
not only a product of their hypoxic microenvironment.
It is therefore important for future studies to determine
the role of these unique metabolic properties in vitro
Fig. 4 (See legend on next page.)
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Fig. 4 Expression profile of Hif-1α and Meis1 in human HPSCs. Expression pattern of Hif-1α a) The left panel shows expression of Hif-1α in human
MPB cells. b) Expression of Hif-1α in human HPSCs. c) Quantification of Hif-1α expression. Note that while 5.3 % of the human MPB cells express
Hif-1α, the significantly higher percentage (47 %) of HPSCs express Hif-1α (~9 fold) (n = 3). Expression pattern of Meis1 d) The left panel shows
expression of Meis1 in human MPB cells. e) Expression of Meis1 in HPSCs. f) The right panel shows quantification of Meis1 expression. Note that
while 6.4 % of the human mobilized peripheral blood cells express Meis1, 48 % of HPSCs express Meis1 (n = 3) (~7.5 fold). Co-expression of Hif-1α
and Meis1 g) Flow cytometric colocalization of Hif-1α and Meis1 in the human MPB cells. Left panel shows a representative flow cytometry profile
of Hif-1α and Meis1 expression. h) Quantification of the percent of Meis1+ cells. Note the majority of Meis1+ cells coexpress Hif-1α. **p < 0.01
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ing therapeutic strategies for hematopoietic disorders.
Methods
Isolation of human mobilized peripheral blood (MPB) cells
Human G-CSF mobilized peripheral blood (MPB) was ob-
tained from bone marrow transplant donors by plasma-
pheresis. Human cells were diluted and separated using
ficoll to obtain the MPB mononuclear cell fraction. Then
cells were suspended at 2–3 × 106 cells/mL in DMEM
media with 10 % fetal bovine serum for flow cytometry.
The study was approved by the Institutional Review Board
of affiliated hospital of UT Southwestern Medical Center
(Dallas, USA) and Shanghai JiaoTong University School of
Medicine (Shanghai, China). Written informed consent
was obtained from each donor for his enrollment. All clin-
ical investigation was conducted in accordance with the
principles expressed in the Declaration of Helsinki.
Flow cytometric profiling and separation of cells based
on mitochondrial potential
Flow cytometric profiling and separation of human MPB
cells based on their mitochondrial activity were performed
by using mitotracker dyes as described previously [3].
Briefly, human MPB cells were enriched by lineage deple-
tion using the BD IMag™ Human Lineage Cell Depletion
Set (BD Biosciences) according to manufacturer’s instruc-
tions. The whole MPB fraction and Lin−CD34+CD38
−CD90+ cells (30 min incubation on ice) were then pro-
filed based on their mitochondrial activity after 15 min
staining with mitotracker dyes (MitoTracker Red FM Cat#
M22425 and MitoTracker Green Cat# M7514, Invitrogen)
at 37 °C (2 × 106 cells/mL, 200 nM mitotracker). Cell
sorting based on high and low mitochondrial activity
was performed using gates that separated the cells with
those with the lowest 7–9 % of mitochondrial activity
and equivalent number of cells with the high mitochon-
drial activity (named low and high mitochondrial po-
tential (MP) cells).
Colony forming assay and in vivo transplantation
Based on mitochondrial profile, colony forming cell
(CFC) assays were performed on human G-CSF MPB
cells. Same numbers of human high and low MP cells
(3 × 104 cells) were plated in each methocult plate(MethoCult® GF H4434, Stem Cell Technologies, USA).
Viability was assessed with trypan blue as this is crucial
that low MP gate often have dying cells with low mito-
chondrial activity. To minimize cell attachment, plates
were precoated with 1 % agarose. After twelve days of
culture, the total number of colonies (per plate) was
counted and the types of colonies were quantified. Note
CFU-GEMM colonies indicate mixed colonies whereas
BFU-E and CFU-GM are measure of erythroid and myeloid
progenitors, respectively. For in vivo transplantation, NOD-
SCID mice were purchased from the Shanghai SLAC La-
boratory Animal Co. Ltd. Five millions of FACS-sorted low
MP or high MP cells in 50 μL of PBS were directly injected
into the tibia as described previously [53]. Human engrafted
cells in bone marrow were detected by using anti-human
CD45 antibodies 2 months after transplantation.
Oxygen consumption
Oxygen consumption was determined using the BD
Oxygen Biosensor System, 384 well (Cat#353,834) ac-
cording to manufacturer’s recommendations. MPB Cells
and human HPSCs were separated as described above.
Equal numbers of cells (5 × 104 cells/well in 50 μL vol-
ume) were incubated up to 6 h in the provided 384 well
plate prior to measurement at Fluostar Optima plate
reader (BMG Labtech). Culture media lacking cells was
used as a negative control and sodium sulfite (100 mM)
was used as a positive control. Oxygen consumption is
presented as relative units.
ATP assay
HPSCs from human MPB Cells were isolated as de-
scribed. Fifty thousand cells were used for each measure-
ment. HPSCs and MPB Cells were centrifuged at 1200 g
for 10 min. ATP standard curves were prepared using
ATP concentrations between 10−6-10−12 M. Then, 50 μl
of ATP standards and 50 μl cell lysates were quantified
using ATP Bioluminescence Assay Kit HS II (Roche)
using Fluostar Optima plate reader (BMG Labtech) fol-
lowing manufacturer instructions. Finally, data were nor-
malized to cell count.
Measurement of 13C lactate production
Cells were cultured in DMEM (Sigma D5030) supple-
mented with L-glutamine (4 mM), NaHCO3 (42.5 mM),
Fig. 5 (See legend on next page.)
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Fig. 5 Transcriptional regulation of Hif-1α by Meis1. a) Real Time PCR of Meis1 in low and high MP cells demonstrates significantly higher levels
of Meis1 expression in low MP cells. b) Upregulation of Meis1 in Kasumi-1 cells compared to human MPB Cells and c) Upregulation of Hif-1α in
Kasumi-1 cells compared to human MPB Cells. d) Real time PCR of Meis1 and Hif-1α in Kasumi-1 cells following siRNA knockdown of Meis1. e)
Real time PCR of lactate dehydrogenase (LDHA), Glut1 (SLC2A1) and phosphofructokinase (PFKL) following siRNA knockdown of Meis1. Note the
significant downregulation of Hif-1α mRNA and Hif-1α target genes following siRNA knockdown of Meis1. f) Relative metabolic shift towards
increased oxidative phosphorylation in Kasumi-1 cells following Meis1 knockdown: There is increased oxygen consumption and ATP levels following
knockdown of Meis1 in Kasumi-1 cells. n = 3,*p < 0.05, **p < 0.01
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Penicillin/Streptomycin and no glucose per well of 96-
well plate. The medium was supplemented with double
labeled 10 mM D-[1-13C, 6-13C]-glucose (Cambridge
Isotope Labs) to allow all of the glucose-derived lactate
pool to be labeled on C-3. Fifty thousand cells (each
well) were cultured in 40 μL of medium for 12 h. After
the culture, the cells were pelleted and an aliquot of 25
μL of the medium was transferred to a glass test tube
with the internal standard (17.9 nmol of Sodium L-
[13C3]-Lactate, Cambridge Isotope Labs). Lactate was
extracted by sequential addition of 1 mL of methanol,
chloroform and water followed by vortexing and centrifuga-
tion at 2000 rpm for 5 min. The aqueous phase was evapo-
rated, derivatized with 100 μLTri-Sil reagent (Pierce) for 30
min at 42 °C, and analyzed by gas chromatography–mass
spectrometry. A three-point standard curve was also pre-
pared using mixtures of un-enriched lactate and L-[3-13C3]-
lactate (Cambridge Isotope Labs). Lactate abundance was
determined by monitoring m/z at 117 (un-enriched), 118
(lactate containing 13C from glucose) and 119 (internal
standard). The areas of 117 and 118 were summed and cor-
rected against the 119 area to calculate total lactate abun-
dance. To determine the atom percent excess (APE), the
117 and 118 areas were first corrected against the 119
abundance to account for inter-sample variability of extrac-
tion. Then the corrected ratio of 118/(117 + 118) was deter-
mined and compared to the standard curve. Finally, the
APE was multiplied by the total nmoles lactate to deter-
mine the nmoles of 13C-lactate produced. The final results
were corrected for total cellular ATP concentration.Metabolic assays with seahore XF96
Oxygen consumption and lactate generation were mea-
sured using the Seahorse XF96 extracellular flux analyzer
as previously described [54]. Briefly, three replicate wells
of 3 × 105 low MP or high MP cells per well were seeded
overnight in 96-well XF96 well plates coated with BD
Cell-Tak (BD Biosciences) in serum-free culture medium
containing 20 ng/ml SCF and 20 ng/ml TPO. One hour
prior to analysis, the medium was replaced by unbuffered
DMEM and the well plates were incubated to 37°C for pH
stabilization. Analyses were performed both at basal con-
ditions and after injection of oligomycin (0.5 μM for OCRor 2 μM for ECAR), FCCP (2 μM), Antimycin A (0.5 μM),
Glucose (10 mM), and 2-DG (100 mM).
Meis1 knockdown
Meis1 siRNA knockdown was carried out in Kasumi-1
cells (human myeloid progenitor cell line known to ex-
press Hif-1α at normoxic conditions [23]). Upregulation
of Meis1 in low MP cells and Kasumi-1 cells compared
to human MPB cells were confirmed by real time PCR.
Kasumi-1 cells were diluted to a density of 200,000 cells
per mL in RPMI media supplemented with 20 % FBS
and antibiotics. The cells were centrifuged for 10 min at
1200 g at 4 °C and suspended in OPTIMEM (Invitrogen).
The cells were then plated into 6-well plates. 12 μL of
Hiperfect (Qiagen) and siRNA (50nM of siRNA per
750,000 cells/well) were incubated in 200 μL of OPTI-
MEM (Invitrogen) for 20 min at RT. Silencer Select Pre-
designed siRNAs (Applied Biosystems, Ambion) for Meis1
were diluted into 50nM stocks (siRNA ID# s8662: 5’-
GGCAUCUACUCGUUCAGGAtt-3’ and 5’-UCCUGAAC
GAGUAGAUGCCgt-3’). siRNA were added to cells drop-
wise and incubated for 6 h. After 6 h incubation, 2.5 mL
RPMI medium was added (20 % FBS and antibiotics) and
plates were incubated under normal growth conditions
for 48 h.
Expression profile of low and high MP cells
PCR arrays (HSC and hypoxia primer sets, SABios-
ciences) were performed to study HPSC and hypoxia in-
ducible gene expression profile of low and high MP
cells. RNA was isolated from low and high MP cells by
TRIzol method (Invitrogen, Carlsbad, CA) following
manufacturer instructions. cDNA was generated by
using an RT-PCR kit (SA biosciences, Maryland, USA).
Real-Time PCR was performed using Human Real-Time
Syber Green PCR Mix (SuperArray) on an ABI Prism
7700 Sequence Detector (Applied Biosystems). The data
was analyzed using the ΔΔCt method. Fold change was
calculated as difference in gene expression between low
and high MP cells.
Real time PCR for Meis1, Hif-1α and Hif-1α related genes
Total RNA was isolated using TRIzol reagent (Invitrogen).
cDNA was generated by following the recommended
Fig. 6 (See legend on next page.)
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Fig. 6 Cooperative role of Pbx1, HoxA9, and Meis1 for transcriptional regulation of Hif-1α. a) Figure shows conserved consensus Meis1, Pbx1, and
HoxA9 motifs found on Hif-1α gene. Note the binding motifs found next to each other in close proximity and highly conserved. b) Luciferase
reporter assays demonstrate dose-dependent transcriptional activation of Hif-1α (Hif-1α-pGL2 reporter) by Pbx1 and mutation of Pbx1 bindings
sites abolished Hif-1α activation (PbxMut-Hif-1α-pGL2 reporter) c) Luciferase reporter assays demonstrate dose-dependent transcriptional activation of
Hif-1α (Hif-1α-pGL2 reporter) by HoxA9 and mutation of HoxA9 bindings sites abolish Hif-1α activation (HoxMut-Hif-1α-pGL2 reporter) d) Luciferase
reporter assays with different combinations of Meis1, Pbx1, and HoxA9 demonstrates (additive) cooperation of Meis1, Pbx1 and HoxA9 for activation of
Hif-1α (Hif-1α-pGL2 reporter) e) Schematic of Meis1, Pbx1 and HoxA9 domains f) Meis1, Pbx1 and HoxA9 protein interaction were assessed by deletion
of pbx1 interaction domain at Meis1 (71-100aa HR1 and 136-180aa HR regions) and Meis1 interaction domain of HoxA9 (1-61aa). Transcriptional activation
by WT vectors, and vectors with deleted domains were evaluated using Hif-1α-pGL2 construct. Luciferase measurements were calculated as firefly luciferase
units versus b-gal units. g) Schematic of proposed model showing regulation of Hif-1α expression by a complex of Meis1/Pbx1/HoxA9 proteins in
hematopoietic stem cells
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trogen) using 2 μg total RNA. Real time PCR was per-
formed with SyberGreen (Applied Biosystems) on ABI
Prism 7700 Sequence Detector (Applied Biosystems)
using primers at Table 1.Intracellular detection of Hif-1α and Meis1 in HPSCs
Human MPB cells and human HPSCs underwent fix-
ation with 4 % paraformaldehyde for 10 min at room
temperature. After permeabilization (0.01 % Triton) and
serum block, cells were incubated overnight with primary
antibodies; 1:50 dilution of anti-Hif-1α (Cat#610958, BD
Transcduction Laboratories) and 1:50 dilution of anti-
Meis1 (sc-10599, Santa Cruz Biotechnology). Staining was
assessed by flow cytometry after incubation with corre-
sponding fluorophore-conjugated secondary antibody.Generation of Meis1 lacking Pbx1 interaction motifs and
HoxA9 lacking Meis1 interaction domain constructs
Meis1 and Pbx1 protein interaction were assessed by de-
letion of Pbx1 interaction domain of Meis1. For that
purpose, we generated Meis1 lacking aminoacids for
Pbx1 interaction domain (both 71–100 aa HR1 and 136-
180aa HR regions) by polymerase chain reaction (PCR)
from pCMV-SPORT6-Meis1 (MMM1013-7512739, Open-
biosystems) using primers (NotI site were inserted for
screening) Meis1dPIM(71–130)F: 5’- ATCTATcatgcggccg
cAAAATGCCTATCGATTTGGTGATAG-3’ and Meis1dTable 1 Primers used in this study








VDU2 [NM_001008563.4] 5’-TAGGGGTCTGPIM(71–130)R: 5’-ATCTATcatgcggccgcTAAAGCGTCAT
TGACCGAGGAACCC-3’.
Meis1 and HoxA9 protein interaction were studied by
co-tranfection of Meis1 with HoxA9 lacking Meis1
interaction domain (MID). HoxA9 lacking aminoacids
for Meis1 interaction domain (1–61) were generated by
PCR from pCMV-SPORT6-HoxA9 (MMM1013-9200573,
Openbiosystems) using primers (BamHI site were inserted
for screening) HoxA9dN(1–61)F: 5’-ATCTATcatggatccCA




Transcriptional activation of Hif-1α reporter by Meis1
(pCMV-SPORT6-Meis1, Cat#MMM1013-7512739,Open
biosystems), Meis1 lacking Pbx1 interaction domain
(Meis1ΔPIM), HoxA9 (pCMV-SPORT6-HoxA9, Cat#
MMM1013-9200573, Openbiosystems), HoxA9 lacking
Meis1 interaction domain (HoxaΔMID) and Pbx1 (pCMV-
SPORT6-Pbx1, Cat# MMM1013-63227,Openbiosystems),
were evaluated using Hif-1α-pGL2 or PbxMut-Hif-1α-
pGL2 (having Pbx1 binding site mutated) or HoxMut-Hif-
1α-pGL2 (having HoxA9 binding site mutated) reporter
constructs as indicated in the figures. 0.8 μg of Hif-1α-
pGL2 or PbxMut-Hif-1α-pGL2 or HoxMut-Hif-1α-pGL2
reporter construct were co-transfectedwith different doses
of the Meis1, Meis1ΔPIM, HoxA9, HoxaΔMID and Pbx1
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reagent (Invitrogen). At 48 h after transfection, cell lysate
were prepared and quantified for firefly luciferase activity
using a luciferase reporter system (Promega). Luciferase
measurements were calculated as firefly luciferase units
versus b-gal units. Transcriptional activation was compared
to basal luciferase levels in cells transfected with Hif-1α-
pGL2 or PbxMut-Hif-1α-pGL2 or HoxMut-Hif-1α-pGL2
and empty pGL2. To test Pbx1 site specificity, Pbx1 bind-
ing site TGATat Hif-1α-pGL2 reporter were mutated using
site directed mutagenesis kit (Strategene) from Hif-1α-




AACACAAGTTTGTAGAAATTG-3’. Similarly, to test
HoxA9 site specificity, HoxA9 binding site ATAA at Hif-1α
reporter using site directed mutagenesis kit from Hif-1α-
pGL2 vector with the following primers: HoxMu-Hif-1α-F:
5’-CCTGTCAGGAGAGCCCAGACGCCGCGTATCAA
TATGTGGCTG CCTC-3’ and HoxMut-Hif-1α-R: 5’-
GAGGCAGCCACATATTGATACGCGGCGTCTG GG
CTCTCCTGACAGG-3’.Western blotting and apoptosis assay
Plasmids of pCMV-SPORT6-Meis1, Meis1ΔPIM, pCMV-
SPORT6-HoxA9 and HoxaΔMID were transfected into
293 T cells. Whole cell lysates were electrophoresed on
8–10 % sodium dodecyl sulfate polyacrylamide gels and
transferred onto polyvinylidene difluoride membranes
(Millipore). The membranes were incubated with primary
antibodies overnight at 4 °C followed by incubation with
appropriate horseradish peroxidase-conjugated secondary
antibodies. The following antibodies were used: anti-
Meis1 (Abcam), anti-HoxA9 (Proteintech) and anti-β-actin
(Calbiochem). For analysis of apoptosis, cells were stained
with PE conjugated anti-annexin V and 7-AAD (BD Phar-
mingen) according to the manufacturer’s instructions.Statistical analysis
Results are expressed as mean ± SEM and a 2-tailed Stu-
dent t test was used to determine the level of signifi-
cance. p < 0.05 was considered statistically different.Additional files
Additional file 1: Figure S1. Clustering and quantification of HSC
frequency and lineages in Low or High MP cells. A) Quantification of HSC
frequency in low MP and high MP cells: HSC (Lin−CD34+CD38−CD90+)
frequency in low MP cells was 1.23 % (4.94 %*0.249 = 1.23 %), which was
around 15-fold higher compared to high MP cells (0.332 %*0.252 = 0.084
%). B) Gating strategy showing clustering of human HPSCs into low and
high MP gates. Human HPSCs clustered into low MP and high MP cells,
where HSPCs were mostly located in low MP gate. C-D) Lineagedistribution was measured in low and high MP cells by flow cytometric
analysis with anti-CD19 and anti-Mac-1 antibodies. (PDF 711 kb)
Additional file 2: Figure S2. A) Quantification of the percentage of
Annexin V+ cells in low MP and high MP cells at normoxia or hypoxia. B)
Representative flow cytometric analysis of repopulation of low MP and
high MP cells. (PDF 324 kb)
Additional file 3: Figure S3. Gating stragegy for Meis1 and Hif-1α
intracellular staining in human MPB Cells (Related to Fig. 4A, 4D, and 4G).
(PDF 730 kb)
Additional file 4: Figure S4. Gating stragegy for Meis1 and Hif-1α
intracellular staining in human HPSCs (Lin−CD34+) (Related to Fig. 4B
and 4E). (PDF 442 kb)
Additional file 5: Figure S5. Knockdown efficiency of Meis1 by siRNA
was examined by western blotting. (PDF 160 kb)
Additional file 6: Figure S6. WT and Deletion mutants (Meis1,
Meis1ΔPIM, HoxA9 and HoxaΔMID) were overexpressed in 293T cells and
detected by western blotting with anti-Meis1 and anti-HoxA9 antibodies.
Both WT and deletion mutants of Meis1, HoxA9 were stably detected.
(PDF 461 kb)
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